<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="topic" /><meta name="keywords" content="Hormone replacement: oestrogens; HRT see Hormone replacement; Menopausal symptoms; Vaginitis: menopausal; Clonidine: menopausal flushing; Hormone replacement: risk table; Contraception: perimenopausal; Hormone replacement: surgery" /><meta name="IX" content="Hormone replacement: oestrogens; Menopausal symptoms; Vaginitis: menopausal; Clonidine: menopausal flushing; Hormone replacement: risk table; Contraception: perimenopausal; Hormone replacement: surgery" /><meta name="IXN" content="HRT see Hormone replacement" /><title>Hormone replacement therapy: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="100039.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="100039.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=100039.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2073.htm">6 Endocrine system</a> &gt; <a href="4297.htm">6.4 Sex hormones</a> &gt; <a href="4298.htm">6.4.1 Female sex hormones</a> &gt; <a href="4299.htm">6.4.1.1 Oestrogens and HRT</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="4299.htm" title="Previous: 6.4.1.1 Oestrogens and HRT">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="4301.htm" title="Next: OESTROGENS FOR HRT">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_100039">Hormone replacement therapy</h1><?highlighter on?><div id="pC" class="jN"><p>Hormone replacement therapy
(HRT) with small doses of an oestrogen (together with a progestogen
in women with a uterus) is appropriate for alleviating menopausal
symptoms such as vaginal atrophy or vasomotor instability. Oestrogen
given systemically in the perimenopausal and postmenopausal period
or tibolone given in the postmenopausal period also diminish postmenopausal
osteoporosis <a title="topic: Osteoporosis" href="100042.htm#_100042">(section 6.6.1)</a> but other drugs (<a title="section: Drugs affecting bone metabolism" href="4439.htm#_4439">section 6.6</a>) are preferred. Menopausal atrophic
vaginitis may respond to a short course of a topical vaginal oestrogen
preparation <a title="sub-section: Preparations for vaginal atrophy" href="4520.htm#_4520">(section 7.2.1) </a>used
for a few weeks and repeated if necessary.</p><p>Systemic therapy with an oestrogen or drugs with oestrogenic
properties alleviates the symptoms of oestrogen deficiency such as
vasomotor symptoms. Tibolone combines oestrogenic and progestogenic
activity with weak androgenic activity; it is given continuously,
without cyclical progestogen.</p><p>HRT may be used in women with early natural or surgical menopause
(before age 45 years), since they are at high risk of osteoporosis.
For early menopause, HRT can be given until the approximate age of
natural menopause (i.e. until age 50 years). Alternatives to HRT should
be considered if osteoporosis is the main concern <a title="section: Drugs affecting bone metabolism" href="4439.htm#_4439">(section 6.6)</a>.</p><p>Clonidine (<a title="monograph: CLONIDINE HYDROCHLORIDE" href="2546.htm#_2546">section 2.5.2</a> and <a title="monograph: CLONIDINE HYDROCHLORIDE" href="3567.htm#_3567">section 4.7.4.2</a>) may be used to reduce vasomotor
symptoms in women who cannot take an oestrogen, but clonidine may
cause unacceptable side-effects.</p><p>HRT increases the risk of venous thromboembolism, stroke, endometrial cancer (reduced by a progestogen), breast cancer,
and ovarian cancer; there is an increased risk of coronary heart disease
in women who start combined HRT more than 10 years after menopause.
For details of these risks see <a title="BNF:target-block: HRT Risk table" href="100039.htm#_204272">HRT Risk table</a>.</p><p>The minimum effective dose of HRT should be used for the shortest
duration. Treatment should be reviewed at least annually and for osteoporosis
alternative treatments considered <a title="section: Drugs affecting bone metabolism" href="4439.htm#_4439">(section 6.6)</a>. HRT does not prevent coronary
heart disease or protect against a decline in cognitive function and
it should <b>not</b> be prescribed for these purposes. Experience
of treating women over 65 years with HRT is limited.</p><p>For the treatment of menopausal symptoms the benefits of short-term
HRT outweigh the risks in the majority of women, especially in those
aged under 60 years.</p><div id="_100039.2"><div class="cAZ"><h2>Risk of breast cancer</h2> <p class="cAX">It is estimated that using <i>all</i> types of HRT, including tibolone, increases the risk
of breast cancer within 1–2 years of initiating treatment, see <a title="BNF:target-block: HRT Risk table" href="100039.htm#_204272">HRT Risk table</a> for details. The increased
risk is related to the duration of HRT use (but not to the age at
which HRT is started) and this excess risk disappears within 5 years
of stopping.</p><p>Radiological detection of breast cancer can be made more difficult
as mammographic density can increase with HRT use; tibolone has only
a limited effect on mammographic density.</p></div></div><div id="_200162"><div class="cAZ"><h2>Risk of endometrial cancer</h2> <p class="cAX">The increased risk
of endometrial cancer depends on the dose and duration of oestrogen-only
HRT, see <a title="BNF:target-block: HRT Risk table" href="100039.htm#_204272">HRT Risk table</a> for details.</p><p>In women with a uterus, the addition of a progestogen cyclically
(for at least 10 days per 28-day cycle) reduces the additional risk
of endometrial cancer; this additional risk is eliminated if a progestogen
is given continuously. However, this should be weighed against the
increased risk of breast cancer.</p></div></div><div class="cAZ"><h2>Risk of ovarian cancer</h2> <p class="cAX">Long-term use of combined
HRT or oestrogen-only HRT is associated with a small increased risk
of ovarian cancer, see <a title="BNF:target-block: HRT Risk table" href="100039.htm#_204272">HRT Risk table</a> for details; this excess
risk disappears within a few years of stopping.</p></div><div id="_100039.3"><div class="cAZ"><h2>Risk of venous thromboembolism</h2> <p class="cAX">Women using combined
or oestrogen-only HRT are at an increased risk of deep vein thrombosis
and of pulmonary embolism especially in the first year of use, see <a title="BNF:target-block: HRT Risk table" href="100039.htm#_204272">HRT Risk table</a> for details.</p><p>In<i> women who have predisposing factors</i> (such as a personal or family history of deep vein thrombosis or
pulmonary embolism, severe varicose veins, obesity, trauma, or prolonged bed-rest) it is prudent
to review the need for HRT, as in some cases the risks of HRT may
exceed the benefits. See below for advice on surgery.</p><p><i>Travel</i> involving prolonged immobility further
increases the risk of deep vein thrombosis, see under Travel in <a title="target-block: Contraceptives -travel" href="4552.htm#_4552.3">section 7.3.1</a>.</p></div></div><div class="cAZ"><h2>Risk of stroke</h2> <p class="cAX">Risk of stroke increases with age,
therefore older women have a greater absolute risk of stroke. Combined
HRT or oestrogen-only HRT slightly increases the risk
of stroke. Tibolone increases the risk of stroke about
2.2 times from the first year of treatment, see <a title="BNF:target-block: HRT Risk table" href="100039.htm#_204272">HRT Risk table</a> for details.</p></div><div class="cAZ"><h2>Risk of coronary heart disease</h2> <p class="cAX">HRT does not prevent
coronary heart disease and should not be prescribed for this purpose.
There is an increased risk of coronary heart disease in women who
start combined HRT more than 10 years after menopause, see <a title="BNF:target-block: HRT Risk table" href="100039.htm#_204272">HRT Risk table</a> for details. Although very
little information is available on the risk of coronary heart disease
in younger women who start HRT close to the menopause, studies suggest
a lower relative risk compared with older women.</p></div><div id="_204272"><div class="cBM" id="_tb0045">HRT Risk</div><table class="table" summary="HRT RiskHormone replacement: risk table" cellspacing="0" cellpadding="8" width="100%" border="0" style="border-collapse: collapse;border-top: 1pt solid ; border-bottom: 1pt solid ; border-left: 1pt solid ; border-right: 1pt solid ; "><colgroup><col /><col /><col /><col /><col /><col /><col /><col /></colgroup><thead><tr><th style="border-right: 1pt solid ; border-bottom: 1pt solid ; " rowspan="2">Risk</th><th style="border-right: 1pt solid ; border-bottom: 1pt solid ; " rowspan="2">Age range (years)</th><th style="border-right: 1pt solid ; border-bottom: 1pt solid ; " colspan="2">Background incidence per 1000 women in Europe not using HRT</th><th style="border-right: 1pt solid ; border-bottom: 1pt solid ; " colspan="2"><b>Additional</b> cases per 1000 women using <b>oestrogen only HRT</b> (estimated)</th><th style="border-right: 1pt solid ; border-bottom: 1pt solid ; " colspan="2"><b>Additional</b> cases per 1000 women using <b>combined (oestrogen-progestogen) HRT</b> (estimated)</th></tr><tr><th style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">Over 5 years</th><th style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">Over 10 years</th><th style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">For 5 years’ use</th><th style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">For 10 years’ use</th><th style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">For 5 years’ use</th><th style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">For 10 years’ use</th></tr></thead><tbody><tr><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; " rowspan="2">Breast cancer<sup class="footnote"><a title="Go to footnote" href="100039.htm#footnote201022">(1)</a></sup></td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">50–59</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">10</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">20</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">2</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">6</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">6</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">24</td></tr><tr><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">60–69</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">15</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">30</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">3</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">9</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">9</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">36</td></tr><tr><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; " rowspan="2">Endometrial cancer<sup class="footnote"><a title="Go to footnote" href="100039.htm#footnote201023">(2)</a></sup><sup class="footnote"><a title="Go to footnote" href="100039.htm#footnote201024">(3)</a></sup></td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">50–59</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">2</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">4</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">4</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">32</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">NS</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">NS</td></tr><tr><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">60–69</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">3</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">6</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">6</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">48</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">NS</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">NS</td></tr><tr><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; " rowspan="2">Ovarian cancer</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">50–59</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">2</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">4</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">&lt;1</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">1</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">&lt;1</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">1</td></tr><tr><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">60–69</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">3</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">6</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">&lt;1</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">2</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">&lt;1</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">2</td></tr><tr><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; " rowspan="2">Venous thromboembolism<sup class="footnote"><a title="Go to footnote" href="100039.htm#footnote201025">(4)</a></sup><sup class="footnote"><a title="Go to footnote" href="100039.htm#footnote201026">(5)</a></sup></td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">50–59</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">5</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; "> </td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">2</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; "> </td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">7</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; "> </td></tr><tr><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">60–69</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">8</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; "> </td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">2</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; "> </td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">10</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; "> </td></tr><tr><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; " rowspan="2">Stroke<sup class="footnote"><a title="Go to footnote" href="100039.htm#footnote201027">(6)</a></sup></td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">50–59</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">4</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; "> </td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">1</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; "> </td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">1</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; "> </td></tr><tr><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">60–69</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">9</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; "> </td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">3</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; "> </td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">3</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; "> </td></tr><tr><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">Coronary heart disease<sup class="footnote"><a title="Go to footnote" href="100039.htm#footnote201028">(7)</a></sup><sup class="footnote"><a title="Go to footnote" href="100039.htm#footnote201029">(8)</a></sup></td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">70–79</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">29–44</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; "> </td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">NS</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; "> </td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; ">15</td><td style="border-right: 1pt solid ; border-bottom: 1pt solid ; "> </td></tr></tbody></table><div class="cAR"><h3>Note</h3> <p class="cAX">Where background incidence or additional
cases have not been included in the table, this indicates a lack of
available data. NS indicates a non-significant difference</p><p>Taken from MHRA/CHM (<i>Drug Safety Update</i> 2007; <b>1</b> (2): 2–6) available at <a href="http://www.mhra.gov.uk/drugsafetyupdate" title="external link">www.mhra.gov.uk/drugsafetyupdate</a></p></div></div><div id="_100039.1"><div class="cAZ"><h2>Choice</h2> <p class="cAX">The choice of HRT for an individual depends
on an overall balance of indication, risk, and convenience. A woman
with a uterus normally requires oestrogen with cyclical progestogen
for the last 12 to 14 days of the cycle <i>or</i> a preparation
which involves continuous administration of an oestrogen and a progestogen
(<i>or</i> one which provides both oestrogenic and progestogenic
activity in a single preparation). <span id="_100039.8">Continuous combined preparations or tibolone
are <b>not suitable</b> for use in the perimenopause or
within 12 months of the last menstrual period; women who use such
preparations may bleed irregularly in the early stages of treatment—if
bleeding continues endometrial abnormality should be ruled out and
consideration given to changing to cyclical HRT.</span></p><p>An oestrogen alone is suitable for continuous use in women without
a uterus. However, in endometriosis, endometrial foci may remain despite
hysterectomy and the addition of a progestogen should be considered
in these circumstances.</p><p>An oestrogen may be given by mouth or by transdermal administration,
which avoids first-pass metabolism. For the use of topical HRT preparations
see <a title=" Preparations for vaginal atrophy" href="4520.htm#_4520">section 7.2.1</a>.</p></div></div><div class="cAZ"><h2>Contraception</h2> <p class="cAX">HRT does <b>not</b> provide
contraception and a woman is considered potentially fertile for 2
years after her last menstrual period if she is under 50 years, and
for 1 year if she is over 50 years. A woman who is under 50 years
and free of all risk factors for venous and arterial disease can use
a low-oestrogen combined oral contraceptive pill (<a title=" Combined oral contraceptives" href="4552.htm#_4552">section 7.3.1</a>) to provide both relief of menopausal
symptoms and contraception; it is recommended that the oral contraceptive
be stopped at 50 years of age since there are more suitable alternatives.
If any potentially fertile woman needs HRT, non-hormonal contraceptive
measures (such as condoms) are necessary.</p><p>Measurement of follicle-stimulating hormone can help to determine
fertility, but high measurements alone (particularly in women aged
under 50 years) do not necessarily preclude the possibility of becoming
pregnant.</p></div><div id="_100039.9"><div class="cAZ"><h2>Surgery</h2> <p class="cAX">Major surgery under general
anaesthesia, including orthopaedic and vascular leg
surgery, is a predisposing factor for venous thromboembolism and it
may be prudent to stop HRT 4–6 weeks before surgery (see Risk of Venous
Thromboembolism, above); it should be restarted only after full mobilisation.
If HRT is continued or if discontinuation is not possible (e.g. in
non-elective surgery), prophylaxis with unfractionated or low molecular
weight <span>heparin</span> and graduated compression hosiery
is advised.</p></div></div><div class="cAZ"><h2>Reasons to stop HRT</h2> <p class="cAX">For circumstances in which
HRT should be stopped, see <a title="target-block: hrt reasons to stop" href="4552.htm#_120027">section 7.3.1</a>.</p></div></div><?highlighter on?><?highlighter off?><div id="pE">◄ <a accesskey="[" href="4299.htm">Previous: 6.4.1.1 Oestrogens and HRT</a> | <a class="top" href="100039.htm#">Top</a> | <a accesskey="]" href="4301.htm">Next: OESTROGENS FOR HRT</a> ►</div><div class="cF"><div class="footnote" id="footnote201022"><sup>(1)</sup>Tibolone increases the risk of breast cancer but to a lesser
extent than with combined HRT.</div><div class="footnote" id="footnote201023"><sup>(2)</sup>Evidence suggests an increased risk of endometrial cancer with
tibolone. After 2.7 years of use (in women of average age 68 years),
1 extra case of endometrial hyperplasia and 4 extra cases of endometrial
cancer were diagnosed compared with placebo users.</div><div class="footnote" id="footnote201024"><sup>(3)</sup>The risk of endometrial cancer cannot be reliably estimated
in those using combined HRT because the addition of progestogen for
at least 10 days per 28-day cycle greatly reduces the additional risk,
and addition of a daily progestogen eliminates the additional risk.
The risk of endometrial cancer in women who have not used HRT increases
with body mass index (BMI); the increased risk of endometrial cancer
in users of oestrogen-only HRT or tibolone is more apparent in women
who are not overweight.</div><div class="footnote" id="footnote201025"><sup>(4)</sup>Limited data does not suggest an increased risk of thromboembolism
with tibolone compared with combined HRT or women not taking HRT.</div><div class="footnote" id="footnote201026"><sup>(5)</sup>Although the level of risk of thromboembolism associated with
non-oral routes of administration of HRT has not been
established, it may be lower for the transdermal route.</div><div class="footnote" id="footnote201027"><sup>(6)</sup>Tibolone increases the risk of stroke about 2.2 times from the
first year of treatment; risk of stroke is age-dependent and therefore
the absolute risk of stroke with tibolone increases with age.</div><div class="footnote" id="footnote201028"><sup>(7)</sup>Increased risk of coronary heart disease in women
who start combined HRT more than 10 years after menopause.</div><div class="footnote" id="footnote201029"><sup>(8)</sup>There is insufficient data to draw a conclusion
on the risk of coronary heart disease with tibolone.</div></div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>